Oh, really...
Thanks for the suggestion. Unfortunately, the friend of 30 years who might have benefited from C-225 died two years ago. I didn't realize that caring for the patient and investing were mutually exclusive.
You are a gem.
The Fox
It was a mistake to reply to you in the first place...guess i was in a bad mood...sorry for your loss...just find it annoying when people talk about biotech co's in a altruistic way when other motives are at play(but not saying you are one of them)...but let us not kid oursleves, we do not come to these boards because we are thinking of loved ones lost...btw, i am a practicing oncologist and trust me, erbitux is no cure all for cancer...frankly , for the cost, its amazing that drugs such as herceptin, erbitux are used as much as they are...now Gleevac is a different story.....also, the chances erbitux would have made a differnce in your friend is very small...the response rates for erbitux/irinotecan is similar(or perhaps slightly higher) to irinotecan alone...even if erbitux showed a 20% response rate by itself, probably wouldnt show a survival benefit unless the number of pt's tested were well into the 1000's(ie-the benefit would be very small)...immunotherapy is not new...has been around for 15 yrs at least and the results are not good...this is no Gleevac, which works very well for certain rare leukemias and stromal gastric cancers...there are so many steps in the cancer process that i doubt blocking one particular step will ever be a "magic bullet"...also, cancer cells are like bacteria, they mutate and develop new ways to be resistent...maybe im just jaded since i deal with cancer everyday...jmho though. |
